Cancer-specific mortality in non-metastatic T1a renal cell carcinoma treated with radiotherapy versus partial nephrectomy.
Cancer-specific mortality
Partial nephrectomy
Radiotherapy
Renal cell carcinoma
Small renal mass
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
received:
29
11
2023
accepted:
06
02
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
epublish
Résumé
Radiotherapy (RT) represents a treatment option for small renal masses with proven feasibility and tolerability. However, it has never been directly compared to partial nephrectomy (PN) with cancer-specific mortality (CSM) as an endpoint. Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified T1aN0M0 renal cell carcinoma (RCC) patients treated with RT or PN. We relied on 1:1 propensity score matching (PSM) for age, tumor size and histology. Subsequently, cumulative incidence plots and multivariable competing risks regression (CRR) models were fitted. The same methodology was then re-applied to a subset of patients with tumor size 21-40 mm. Of 40,355 patients with T1aN0M0 RCC, 40,262 underwent PN (99.8%) vs 93 underwent RT (0.2%). RT patients were older (median age 72 vs 60 years, p < 0.001) and harbored larger tumor size (median size 28 vs 25 mm, p < 0.001) and a higher proportion of non-clear cell RCC (49% vs 22%, p < 0.001). After 1:1 PSM (92 RT versus 92 PN patients), cumulative incidence plots' derived CSM was 21.3 vs 4%, respectively. In multivariable CRR models, RT independently predicted higher CSM (hazard ratio (HR) 4.3, p < 0.001). In the subgroup with tumor size 21-40 mm, after 1:1 PSM (72 RT versus 72 PN patients), cumulative incidence plots derived CSM was 21.3% vs 4%, respectively. In multivariable CRR models, RT also independently predicted higher CSM (HR 4.7, p = 0.001). In T1aN0M0 RCC patients, relative to PN, RT is associated with significantly higher absolute and relative CSM, even in patients with tumor size 21-40 mm.
Identifiants
pubmed: 38530480
doi: 10.1007/s00345-024-04856-y
pii: 10.1007/s00345-024-04856-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Pandolfo SD, Carbonara U, Beksac AT, Derweesh I, Celia A, Schiavina R et al (2023) Microwave versus cryoablation and radiofrequency ablation for small renal mass: a multicenter comparative analysis. Miner Urol Nephrol 75(1):34
Pandolfo SD, Beksac AT, Derweesh I, Celia A, Schiavina R, Bianchi L et al (2023) Percutaneous ablation vs robot-assisted partial nephrectomy for completely endophytic renal masses: a multicenter trifecta analysis with a minimum 3-year follow-up. J Endourol 37(3):279–285
doi: 10.1089/end.2022.0478
pubmed: 36367175
Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z et al (2023) Cancer-specific mortality in T1a renal cell carcinoma treated with local tumor destruction versus partial nephrectomy. Eur Urol Focus 9(1):125–132
doi: 10.1016/j.euf.2022.07.005
pubmed: 35918270
Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS et al (2022) The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol 82(6):613–622
doi: 10.1016/j.eururo.2022.06.017
pubmed: 35843777
Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L et al (2019) The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus 5(6):958–969
doi: 10.1016/j.euf.2019.06.002
pubmed: 31248849
Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ et al (2022) 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23(12):1508–1516
doi: 10.1016/S1470-2045(22)00656-8
pubmed: 36400098
The R Project for Statistical Computing. https://www.r-project.org
Grubb WR, Ponsky L, Lo SS, Kharouta M, Traughber B, Sandstrom K et al (2021) Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol 155:138–143
doi: 10.1016/j.radonc.2020.10.031
pubmed: 33214131
Tetar SU, Bohoudi O, Senan S, Palacios MA, Oei SS, van der Wel AM et al (2020) The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer. Cancers (Basel) 12(10):2763
doi: 10.3390/cancers12102763
pubmed: 32992844
Swaminath A, Cheung P, Glicksman RM, Donovan EK, Niglas M, Vesprini D et al (2021) Patient-reported quality of life following stereotactic body radiation therapy for primary kidney cancer—results from a prospective cohort study. Clin Oncol 33(7):468–475
doi: 10.1016/j.clon.2021.03.002
Hanzly M, Creighton T, Mix M, Zeeck K, Fung-Kee-Fung S, Singh AK et al (2014) Stereotactic body radiotherapy for the treatment of renal tumors. Urol Case Rep 2(5):147–149
doi: 10.1016/j.eucr.2014.05.011
pubmed: 26958469
pmcid: 4782072
Lo CH, Huang WY, Chao HL, Lin KT, Jen YM (2014) Novel application of stereotactic ablative radiotherapy using CyberKnife
doi: 10.3892/ol.2014.2129
pubmed: 24959276
pmcid: 4063570
Grelier L, Baboudjian M, Gondran-Tellier B, Couderc AL, McManus R, Deville JL et al (2021) Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience. Cancers (Basel) 13(13):3129
doi: 10.3390/cancers13133129
pubmed: 34201451
Siva S, Correa RJM, Warner A, Staehler M, Ellis RJ, Ponsky L et al (2020) Stereotactic ablative radiotherapy for ≥T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int J Radiat Oncol Biol Phys 108(4):941–949
doi: 10.1016/j.ijrobp.2020.06.014
pubmed: 32562838
Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH et al (2017) Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 120(5):623–630
doi: 10.1111/bju.13811
pubmed: 28188682
Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A et al (2011) A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 59(4):543–552
doi: 10.1016/j.eururo.2010.12.013
pubmed: 21186077
Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner KM et al (2006) A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol (Madr) 45(7):870–875
doi: 10.1080/02841860600954875